Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Celgene

Takeda Pharmaceutical

Telesis Bio Inc

The most prominent positions in Seth Klarman (Trades, Portfolio) equity portfolio are well-known and covered by the financial media.

Seth Klarman's Favorite Biotech Positions

AstraZeneca

Johnson & Johnson

Eli Lilly

Merck

Roche Holding AG

Sanofi

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Shareholders are hoping the acquisition and new leadership will energize the stock price.

Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal

Acceleron Pharma

Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

ABIOMED

Amgen

Stryker

Teladoc

These beaten-down healthcare stocks still have plenty of long-term potential. Here's what investors need to know about each.

5 Healthcare Stocks to Pick Up From the Wreckage

bluebird bio

Exelixis

Guardant Health Inc

Illumina

These stocks are leading the way in their respective areas in battling cancer.

Top 5 Stocks in the Fight Against Cancer

Novartis

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Bristol-Myers stock is cheap, but investors are sitting on the sidelines ahead of the Celgene merger, an analyst said Wednesday. The deal is now expected to close late in the third quarter.

The Celgene Merger Looks Secure — So Why Is Bristol Under Pressure?

AbbVie

BMY and ABBV currently face short-term challenges, but both are working hard to overcome those challenges.

Bristol-Myers Squibb And AbbVie: Pharma Dividend Opportunities With Large Margins Of Safety

Shares of biotech company Celgene jumped Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.

Can This Biotech Extend Its Breakout As FDA Reviews Anemia Drug?

Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.

Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO

ConocoPhillips

CVS Health

Wells Fargo

According to GuruFocus’ list of 52-week lows, these Guru stocks have reached their 52-week lows.

These Guru stocks have reached their 52-week lows

Gilead Sciences

Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO

Wells Fargo & Co., United Parcel Service Inc., Gilead Sciences Inc. and Bristol-Myers Squibb Company.

Stocks That Fell to 3-Year Lows in the Week of May 31

In the latest trading session, Bristol-Myers Squibb (BMY) closed at $45.37, marking a -1.11% move from the previous day.

Bristol-Myers Squibb (BMY) Stock Moves -1.11%: What You Should Know

Novo Nordisk

BMY vs. NVO: Which Stock Is the Better Value Option?

BMY or NVO: Which Is the Better Value Stock Right Now?

Biogen

Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma

Pfizer

And the analyst really likes one in particular.

This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy.

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Bristol-Myers Squibb Co's quest to expand its oncology franchise through its proposed acquisition of Celgene Corporation may not be a wise move, according to Argus.

Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

British American Tobacco

I'm a huge proponent of buying blue-chip dividend stocks at fair value or better. Sometimes the market offers quality companies at VERY large discounts to intrinsic value.

These 3 High-Yield Blue Chips Are Very Strong Buys

The Bristol-Myers deal with Celgene includes a $9 CVR component.

Valuing Celgene's Contingent Value Rights

Nektar Therapeutics

Nektar Therapeutics stock popped Thursday after the company said it would present new data for a Bristol-partnered cancer treatment in June.

This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom

Bristol-Myers Squibb Co (NYSE: BMY), which is prepping for its purchase of Celgene Corporation (NASDAQ: CELG), announced Thursday that its cancer immunotherapy drug Opdivo failed in a late-stage study evaluating it as a brain cancer treatment.

News for Bristol-Myers Stock (BMY)